Global CAR T-Cell Therapy Market 2030 by Drug type, Indication, Target Antigen, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints

The CAR T-Cell Therapy Market size is estimated to grow from USD 8.2 Billion in 2022 to reach USD 11.2 Billion by 2030, growing at a CAGR of 23.8% during the forecast period from 2023 to 2030.

Major players CAR T-Cell Therapy Market include: Pfizer, Inc., Cellectis, Caribou Biosciences, Inc., Celyad Oncology, Merck & Co., Inc., Celgene Corporation, Juno Therapeutics, Inc., Sorrento Therapeutics, Inc., Bluebird Bio, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Cartesian Therapeutics, Inc., Bristol-Myers Squibb, Miltenyi Biotech, Autolus Therapeutics, Novartis AG and Others.

The Growth of CAR T-Cell Therapy Market Driven by Remarkable Efficacy and Potential to Treat Certain Types of Cancer

CAR T-cell therapy has emerged as a significant driver in the market due to its exceptional efficacy and potential to treat previously challenging and limited cancer types. Notably, hematological malignancies, including specific types of leukemia and lymphoma, have witnessed impressive results with CAR T-cell therapy, where conventional treatments like chemotherapy and radiation therapy often had limited success. The therapy involves genetic modification of a patient's T cells to express chimeric antigen receptors (CARs), enabling them to recognize and target cancer cells with specific antigens. This targeted approach allows CAR T cells to selectively attack cancer cells, sparing healthy cells, leading to improved outcomes and reduced side effects compared to traditional treatments. Clinical trials and real-world data have showcased significant and long-lasting responses in patients with refractory or relapsed cancers, offering the potential for cure or long-term remission in some cases. These success stories have garnered substantial interest from healthcare providers, patients, and investors, driving further research, investment, and adoption of this innovative therapy. Furthermore, regulatory agencies' approvals of CAR T-cell therapies for specific indications have played a pivotal role in market growth. As more CAR T-cell therapies receive regulatory approvals and expand into new cancer indications, the market is expected to experience significant expansion in the coming years.

Increase in Incidence of Cancer and Strong Product Pipeline to Drive Global Market

The global CAR T-cell therapy market is poised for growth, driven by an increase in cancer incidence and a robust product pipeline. According to the World Health Organization (WHO), one in five individuals develops cancer during their lifetime, with one in eight men and one in 11 women succumbing to the disease. Additionally, over 50 million people are estimated to be living within five years of a previous cancer diagnosis. The rising need for effective cancer treatments is further underscored by the approximately 544,352 new cases of non-Hodgkin lymphoma reported globally in 2020. The presence of a strong product pipeline is a crucial factor stimulating demand for CAR T-cell therapy products. Notably, Autolus Therapeutics plc is leading the way with its innovative product named AUTO1, currently undergoing phase I trials for the treatment of adult acute lymphoblastic leukemia. AUTO1 features obecabtageneautoleucel, an investigational CD19 CAR T-cell therapy designed to overcome limitations observed in current CD19 CAR T-cell therapies, addressing concerns related to clinical activity and safety. These promising developments in the CAR T-cell therapy market are expected to drive its expansion and have a positive impact on the treatment landscape for cancer patients.

North America Dominated the CAR T-Cell Therapy Market during the forecast period

In 2022, North America dominated in the global CAR T-cell therapy market, leading both in terms of growth and market share. Within North America, the U.S. CAR T-cell therapy market is projected to continue its leadership position throughout the forecast period. The market growth in the U.S. is primarily fueled by high healthcare expenditure and significant advancements in CAR T-cell therapy treatment procedures. The recent FDA approvals of ground breaking CAR T-cell therapies have been instrumental in expanding the market, particularly in the treatment of blood cancer, leukemia, and myeloma. To further promote awareness and understanding of CAR T-cell therapies, healthcare organizations and manufacturers in the U.S. actively engage in comprehensive awareness campaigns aimed at educating patients about this revolutionary therapy. These initiatives have successfully stimulated demand and created a favorable market landscape. Meanwhile, the Canadian CAR T-cell therapy market is expected to experience a healthy compound annual growth rate (CAGR) in the upcoming years, closely following the trajectory of the U.S. market during the forecast period. This growth in Canada is driven by increasing investments by prominent industry players in advancing CAR T-cell therapy and the presence of favorable reimbursement policies in the country.

On the other hand, The Asia-Pacific region is projected to experience the highest growth rate during the forecast period, and China, in particular, is leading the way with its burgeoning market. China has seen a surge in registered clinical trials for CAR-T therapies, making it a promising and viable market for these treatments in recent times. The region's remarkable progress in the CAR T-cell therapy market can be attributed to dedicated efforts in government spending and reforms, fostering significant development in the industry.

The CAR T-Cell Therapy Market research report provides an in-depth overview of the industry including market segmentation by Drug Type, Indication, Target Antigen, End-user and Region. Analysis of the global market with special focus on high growth application in each vertical and fast-growing market segments. It includes detailed competitive landscape with identification of the key players with respect to each type of market, in-depth market share analysis with individual revenue, market shares, and top players rankings. Impact analysis of the market dynamics with factors currently driving and restraining the growth of the market, along with their impact in the short, medium, and long-term landscapes. Competitive intelligence from the company profiles, key player strategies, game-changing developments such as new product launch, collaborations, expansions, investment analysis, mergers and acquisitions.

CAR T-Cell Therapy Market is segmented by region and further by countries, Drug Type, Indication, Target Antigen, End-user and Region. Players, stakeholders, and other participants in the global CAR T-Cell Therapy Market will be able to gain a strong position as this report will surely benefit their marketing strategies. The market analysis focuses on revenue and forecast by region/countries and by application in terms of revenue forecast for the period 2023-2030.

Report further studies the market strategies of key players, recent development status, future plans and CAR T-Cell Therapy Market trends across the world. Also, it splits CAR T-Cell Therapy Market Segmentation by material, end-user and region to deep dive research and reveals company profile and prospects.

Major Classifications are as follows:

By Drug Type

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Carvykti (ciltacabtagene autoleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Others

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia (CLL)
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma (MM)
• Others

By Target Antigen

• CD 19
• CD 20
• GD2
• CD22
• CD30
• CD33
• HER1
• HER2
• Others

By End user

• Hospitals
• Cancer Treatment Centers
• Others

By Region

• North America
• US
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Rest of Asia Pacific
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa

Reason to Purchase this CAR T-Cell Therapy Market Report:

• Determine prospective investment areas based on a detailed trend analysis of the global CAR T-Cell Therapy Market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different and CAR T-Cell Therapy Market segments in the top spending countries across the world and identify the opportunities offered by each of them.
• Strengthen your understanding of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels that are driving the global CAR T-Cell Therapy Market, providing a clear picture of future opportunities that can be tapped, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs that are being undertaken by the different countries within the global CAR T-Cell Therapy Market.
• Make correct business decisions based on a thorough analysis of the total competitive landscape of the sector with detailed profiles of the top CAR T-Cell Therapy Market providers around the world which include information about their products, alliances, recent contract wins and financial analysis wherever available.

This product will be delivered within 3-5 business days.